ECO Animal Health Group announced on Wednesday that its subsidiary ECO Animal Health Limited has received a marketing authorisation from the Thailand Food and Drug Administration for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.
The AIM-traded firm said the approval – the first following the European approval in June – will allow it to start selling Aivlosin in Thailand for the medication of drinking water for the treatment of respiratory infection caused by Mycoplasma gallisepticum in egg-laying poultry, with a zero day drug withdrawal period for eggs.
Patented antimicrobial Aivlosin is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric diseases in poultry and pigs, the board explained.
“This approval from the Thai FDA is an important step in the development of Aivlosin®for commercial layers with Thailand being ranked as a global top twenty egg producing country,” said chairman Peter Lawrence.
“ECO has begun the process of submitting the Aivlosin regulatory files for the treatment of layers in numerous other key egg producing markets.
“It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”